ATE399014T1 - Nukleinsäuren zur behandlung von erkrankungen im zusammenhang mit hmgb1 - Google Patents

Nukleinsäuren zur behandlung von erkrankungen im zusammenhang mit hmgb1

Info

Publication number
ATE399014T1
ATE399014T1 AT05773148T AT05773148T ATE399014T1 AT E399014 T1 ATE399014 T1 AT E399014T1 AT 05773148 T AT05773148 T AT 05773148T AT 05773148 T AT05773148 T AT 05773148T AT E399014 T1 ATE399014 T1 AT E399014T1
Authority
AT
Austria
Prior art keywords
treatment
hmgb1
nucleic acids
diseases related
nucleic acid
Prior art date
Application number
AT05773148T
Other languages
English (en)
Inventor
Domenico Barone
Marco Bianchi
Enrico Bucci
Silvano Fumero
Margherita Valente
Roberto Sapio
Domenica Musumeci
Original Assignee
Creabilis Therapeutics Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35106975&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE399014(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Creabilis Therapeutics Spa filed Critical Creabilis Therapeutics Spa
Application granted granted Critical
Publication of ATE399014T1 publication Critical patent/ATE399014T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
    • C12N2310/3181—Peptide nucleic acid, PNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/52—Physical structure branched

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT05773148T 2004-07-02 2005-07-04 Nukleinsäuren zur behandlung von erkrankungen im zusammenhang mit hmgb1 ATE399014T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58467804P 2004-07-02 2004-07-02
US64658605P 2005-01-26 2005-01-26

Publications (1)

Publication Number Publication Date
ATE399014T1 true ATE399014T1 (de) 2008-07-15

Family

ID=35106975

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05773148T ATE399014T1 (de) 2004-07-02 2005-07-04 Nukleinsäuren zur behandlung von erkrankungen im zusammenhang mit hmgb1

Country Status (14)

Country Link
US (1) US20080305073A1 (de)
EP (1) EP1768677B1 (de)
JP (1) JP2008504335A (de)
AT (1) ATE399014T1 (de)
AU (1) AU2005259381A1 (de)
BR (1) BRPI0512944A (de)
CA (1) CA2572519A1 (de)
DE (1) DE602005007746D1 (de)
DK (1) DK1768677T3 (de)
ES (1) ES2306195T3 (de)
IL (1) IL179828A0 (de)
PL (1) PL1768677T3 (de)
PT (1) PT1768677E (de)
WO (1) WO2006002971A2 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA012082B1 (ru) 2004-08-03 2009-08-28 Транстек Фарма, Инк. Белки слияния на основе rage и способы их использования
US20100172909A1 (en) * 2005-10-24 2010-07-08 Masahiro Nishibori Cerebral edema suppressant
WO2007094926A2 (en) * 2006-02-09 2007-08-23 Transtech Pharma, Inc. Rage fusion proteins and methods of use
JP3882090B1 (ja) * 2006-05-19 2007-02-14 国立大学法人 岡山大学 脳血管攣縮抑制剤
JP2010509912A (ja) * 2006-11-17 2010-04-02 クリニカル ジーン ネットワークス アーベー 遺伝子ｇｙｐｃ、ａｇｐａｔ３、ａｇｌ、ｐｖｒｌ２、ｈｍｇｂ３、ｈｓｄｌ２および／またはｌｄｂ２に関連するスクリーニングおよび治療方法
CN101589309A (zh) * 2006-11-17 2009-11-25 临床基因网络公司 涉及基因gypc、agpat3、agl、pvrl2、hmgb3、hsdl2和/或ldb2的筛选和治疗方法
US8927510B2 (en) 2008-05-16 2015-01-06 Children's Medical Center Corporation Compositions and methods for inhibition of retroviruses
JP5559159B2 (ja) 2008-06-11 2014-07-23 バイオニュークレオン ソチエタ・レスポンサビリタ・リミタータ 修飾オリゴヌクレオチドを使用するｈｒｐ−３の阻害
JP5710482B2 (ja) 2008-09-11 2015-04-30 アンスティテュ・パストゥール Ｈｍｇｂ１依存型誘発のｈｉｖ−１複製および持続の調節によるヒト免疫不全ウイルス感染の監視および阻害
US20120165244A1 (en) * 2008-10-30 2012-06-28 Hua-Lin Wu Methods for binding lewis y antigen
MY171292A (en) 2008-12-22 2019-10-07 Creabilis S A Synthesis of polymer conjugates of indolocarbazole compounds
BRPI1015019A2 (pt) 2009-04-20 2018-02-14 Pfizer controle de glicosilação de proteína e composições e métodos relacionada a ele.
GB0911569D0 (en) * 2009-07-03 2009-08-12 Ulive Entpr Ltd Method for the detection of organ or tissue injury
JP5467313B2 (ja) * 2009-09-28 2014-04-09 国立大学法人 岡山大学 アテローム動脈硬化抑制剤
US8975019B2 (en) * 2009-10-19 2015-03-10 University Of Massachusetts Deducing exon connectivity by RNA-templated DNA ligation/sequencing
EP2617426B1 (de) * 2010-09-17 2016-08-10 Japan Science and Technology Agency Hemmer der hmgb-protein-vermittelten immunantwortaktivierung
US20140378531A1 (en) * 2012-02-01 2014-12-25 New York University Inhibition of pattern recognition receptors in pancreatic cancer treatment using tlr inhibitors
JP6624542B2 (ja) * 2015-02-05 2019-12-25 国立大学法人広島大学 ヒトｈｍｇｂ１結合剤およびヒトｈｍｇｂ１除去装置
WO2018175340A1 (en) 2017-03-20 2018-09-27 Sienna Biopharmaceuticals, Inc. Reduced exposure conjugates modulating therapeutic targets
WO2018175315A1 (en) 2017-03-20 2018-09-27 Sienna Biopharmaceuticals, Inc. Polymer conjugates of staurosporine derivatives having reduced exposure
WO2018175302A1 (en) 2017-03-20 2018-09-27 Sienna Biopharmaceuticals, Inc. Polymer conjugates targeting c-src with reduced exposure
WO2018175301A1 (en) 2017-03-20 2018-09-27 Sienna Biopharmaceuticals, Inc. Polymer conjugate of montesanib with reduced exposure
WO2018208369A1 (en) 2017-05-10 2018-11-15 Sienna Biopharmaceuticals, Inc. Uses of polymer conjugates of indolocarbazole compounds with reduced exposure
CN111304202B (zh) * 2020-02-26 2023-03-28 西安交通大学 一种用于识别且增强hmgb1生物学活性的核酸适配子及其应用
CN114957440A (zh) * 2022-05-26 2022-08-30 江苏大学 一种重组HMGB1 A Box蛋白及其获取方法与应用
WO2023250249A1 (en) * 2022-06-23 2023-12-28 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Hmgb1 inhibitors for treatment of apoe4-related tauopathies including alzheimer's disease
CN114807150B (zh) * 2022-06-28 2022-10-14 中国科学院基础医学与肿瘤研究所(筹) 靶向和拮抗hmgb1分子的核酸适体
CN115774004B (zh) * 2022-08-19 2024-07-05 四川大学华西医院 二氧化锆@量子点复合微球在制备检测hmgb1的荧光探针中的用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE256200T1 (de) * 1992-10-14 2003-12-15 Nexstar Pharmaceuticals Inc Methode zur selektion von nukleinsäuren auf der basis ihrer struktur
ITMI20010562A1 (it) * 2001-03-16 2002-09-16 Marco E Bianchi Inibitori o antagonisti della proteina hmg1 per il trattamento di disordini vascolari
NZ540067A (en) * 2002-11-20 2007-05-31 Critical Therapeutics Inc A purified preparation of antibodies that specifically bind to a high mobility group box protein (HMGB) B box but do not specifically to non-B box epitopes of HMGB

Also Published As

Publication number Publication date
AU2005259381A1 (en) 2006-01-12
DK1768677T3 (da) 2008-10-20
CA2572519A1 (en) 2006-01-12
JP2008504335A (ja) 2008-02-14
DE602005007746D1 (de) 2008-08-07
WO2006002971A3 (en) 2006-04-20
EP1768677B1 (de) 2008-06-25
WO2006002971A2 (en) 2006-01-12
EP1768677A2 (de) 2007-04-04
PT1768677E (pt) 2008-10-06
US20080305073A1 (en) 2008-12-11
BRPI0512944A (pt) 2008-04-15
ES2306195T3 (es) 2008-11-01
IL179828A0 (en) 2008-03-20
PL1768677T3 (pl) 2009-01-30

Similar Documents

Publication Publication Date Title
ATE399014T1 (de) Nukleinsäuren zur behandlung von erkrankungen im zusammenhang mit hmgb1
ATE447551T1 (de) Biphenyloxyessigsäure - derivate zur behandlung von atemwegserkränkungen
ATE519488T1 (de) Aminopyrazin-analoga zur behandlung von glaukomen und anderen durch rho-kinase verursachten krankheiten
ATE550338T1 (de) Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
DE502005010615D1 (de) Mittel zur behandlung von entzündlichen erkrankungen
DE602006019838D1 (de) Piperazinsubstituierte benzothiophene zur behandlung von geisteskrankheiten
ATE540949T1 (de) Substituierte pteridine zur behandlung von entzündlichen erkrankungen
ATE512663T1 (de) Kombination zur behandlung von erkrankungen mit zellproliferation
DE502005009604D1 (de) Verfahren zur herstellung von ameisensäure
ATE506951T1 (de) Als inhibitoren von beta-secretase aktive tertiäre carbinamine mit substituierten heterocyclen zur behandlung der alzheimer- krankheit
DE602005017027D1 (de) Verfahren zur enzymatischen herstellung von (s)-3-cyano-5-methylhexansäure
DE602004022061D1 (de) Verwendung von modifizierten cyclosporinen zur behandlung von hcv-erkrankungen
ATE504580T1 (de) Malonsäureamidderivate als inhibitoren von g- sekretase zur behandlung von alzheimer-krankheit
EA200600735A1 (ru) Нуклеиновые кислоты, специфично связывающие биоактивный грелин
ATE383853T1 (de) Arylessigsäuren und verwandte verbindungen zur behandlung von alzheimer-krankheit
DE602004016729D1 (de) 1-phenylalkancarbonsäurederivate zur behandlung neurodegenerativer erkrankungen
ATE496913T1 (de) Neue, langwirksame betamimetika zur behandlung von atemwegserkrankungen
ATE472998T1 (de) Kationische liposomale zubereitungen zur behandlung von rheumatoider arthritis
DE602005016141D1 (de) S-mirtazapin zur behandlung von hitzewallungen
DE602005013650D1 (de) Proteinhydrolysat zur behandlung von müdigkeit
ATE521631T1 (de) Verwendung von aimp2dx2 zur diagnose und behandlung von krebs
EA201070496A1 (ru) УГЛЕРОД-СВЯЗАННЫЕ МОДУЛЯТОРЫ γ-СЕКРЕТАЗЫ
ATE442382T1 (de) Ein die mam-domäne enthaltendes protein
DE60124255D1 (de) Verwendung von exogenen milchsäurebakterien zur behandlung von durch actinomyces naeslundii hervorgerufenen krankheiten
ATE454147T1 (de) Verwendung von pyrazolopyridinen zur behandlung von kognitiven defiziten

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1768677

Country of ref document: EP

RZN Patent revoked